NANAIMO, British Columbia--(BUSINESS WIRE)--Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Sascha Mielcarek as Managing Director, Europe.
Sascha Mielcarek comes to Tilray with over 18 years of experience in the pharmaceutical industry bringing extensive global commercial sales and marketing expertise in international markets such as the U.S., Europe and Latin America. Sascha most recently was at Grünenthal as Global Head of Gout Business Unit & Alliance Implementation Lead.
“The expansion of our European senior leadership team strengthens Tilray’s ability to enter into new addressable markets and solidify our presence in existing European markets,” says Brendan Kennedy, Tilray CEO. “Sascha brings an unmatched level of expertise from his years of experience in the European and global pharmaceutical industry and we’re very pleased to welcome him to our team.”
Tilray has a pioneering track-record as a company committed to making pharmaceutical-grade medical cannabis products available to patients in-need all over the world. With global operations currently located Australia & New Zealand, Canada, Germany, Latin America, and Portugal, Tilray is well-positioned to expand the availability of its branded cannabis products in other countries as regulations allow. Tilray has already successfully exported within Europe to: Czech Republic, Germany, United Kingdom, Cyprus and Croatia, and outside of Europe to, Argentina, Chile, United States, South Africa, Australia and New Zealand.
In the new role of Managing Director, Europe, Sascha will provide strategic leadership to Tilray’s existing European team as it pursues new market entries in Europe and continues to strengthen the company’s position in existing markets. Sascha and his team will be working collaboratively with Tilray’s team of experts at the state-of-the-art facility in Cantanhede, Portugal, which will act as the primary hub for the cultivation, processing, research and distribution of branded Tilray products throughout Europe, once fully licensed.
Sascha joins Tilray’s recent global senior leadership hires: Greg Christopher as EVP of Operations, Rita Seguin as EVP of Human Resources, Dara Redler as General Counsel and Charlie Cain as VP of Retail. Tilray looks forward to sharing more information about the expansion of its global leadership team and operations within Europe.
About Tilray®
Tilray (NASDAQ:TLRY) is a global pioneer in
the research, cultivation, production and distribution of cannabis and
cannabinoids currently serving tens of thousands of patients and
consumers in twelve countries spanning five continents.
Cautionary Note Regarding Forward-looking Statements
This
press release contains “forward-looking statements” within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 and
“forward-looking information” within the meaning of Canadian securities
laws, or collectively, forward-looking statements. Forward-looking
statements in this press release may be identified by the use of words
such as, “may”, “would”, “could”, “will”, “likely”, “expect”,
“anticipate”, “believe, “intend”, “plan”, “forecast”, “project”,
“estimate”, “outlook” and other similar expressions and include
statements relating to the global success of the Tilray. Forward-looking
statements are not a guarantee of future performance and are based upon
a number of estimates and assumptions of management in light of
management’s experience and perception of trends, current conditions and
expected developments, as well as other factors that management believes
to be relevant and reasonable in the circumstances, including
assumptions in respect of current and future market conditions, the
current and future regulatory environment and future approvals and
permits. Actual results, performance or achievement could differ
materially from that expressed in, or implied by, any forward-looking
statements in this press release, and, accordingly, you should not place
undue reliance on any such forward-looking statements and they are not
guarantees of future results. Forward-looking statements involve
significant risks, assumptions, uncertainties and other factors that may
cause actual future results or anticipated events to differ materially
from those expressed or implied in any forward-looking statements.
Please see the heading “Risk Factors” in Tilray’s Quarterly Report on
Form 10-Q, which was filed with the Securities and Exchange Commission
and Canadian securities regulators on November 14, 2018, for a
discussion of the material risk factors that could cause actual results
to differ materially from the forward-looking information. Tilray does
not undertake to update any forward-looking statements that are included
herein, except in accordance with applicable securities laws.
